Navigation Links
Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
Date:2/5/2008

BOSTON, Feb. 5 /PRNewswire-USNewswire/ -- A new study led by researchers at Joslin Diabetes Center has identified insulin resistance in the liver as a key factor in the cause of metabolic syndrome and its associated atherosclerosis, disorders that put tens of millions of Americans at high risk of cardiovascular disease.

The findings, published in the February issue of Cell Metabolism, provide not only an understanding of how metabolic syndrome occurs, but also pinpoint a target for treatment of the condition. This represents the work of Sudha Biddinger, M.D., Ph.D., and a team led by C. Ronald Kahn, M.D., Head of the Joslin Research Section on Obesity and Hormone Action and the Mary K. Iacocca Professor of Medicine at Harvard Medical School.

"This is one of the first true insights into the role of the liver in the metabolic syndrome and provides guidance for future therapies," said senior investigator Dr. Kahn, an internationally recognized researcher in diabetes and metabolism. "Showing this connection between atherosclerosis and insulin resistance is one of the most dramatic findings I've seen in 35 years."

Metabolic syndrome is a collection of medical problems related to insulin resistance, including obesity, glucose intolerance, hypertension, lowered HDL ("good") cholesterol and elevated triglycerides. Together these are associated with an increased risk of atherosclerosis, the buildup of plaque in the coronary arteries that leads to heart attack and stroke.

"This study clearly indicates that metabolic syndrome is not merely a collection of abnormalities that should be considered and treated independently, as some experts have advocated," said Kahn and Biddinger. "Rather, it appears that metabolic syndrome is truly a group of closely linked disturbances in glucose and cholesterol metabolism that stem from a defect in insulin signaling in the liver."

The research was funded in part by grants from the National In
'/>"/>

SOURCE Joslin Diabetes Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
2. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
3. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
4. Inverseon Announces Positive Phase IIa Asthma Study
5. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
6. Study Says Allergy Shots Help Children, Reduce Health Care Costs
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
9. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
10. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
11. Northwestern Memorial Transplant Program Initiates New Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...., Sept. 5 /PRNewswire-USNewswire/ -- A team of,re...at U.S. immigrants from,India and Pakistan take on...heir risks of prostate cancer among male immigrant...r and prostate cancer develop due to many reasons,...jor role in these cancers,",said Jame Abraham, M.D...
(Date:9/4/2008)... in TaqMan(R) real-time PCR testing for the diagno...NTON, Calif., Sept. 4 /- The U.S. Foo...he COBAS(R) TaqMan(R) HBV Test,the first assay fo...he U.S.,The test uses Roche,s real-time PCR techno...NA in a patient,s blood. Doctors may use viral loa...
(Date:9/4/2008)...and, September 4 /- Axentis Pharma AG...s the safety and tolerability,of a new therapeutic...,infection in cystic fibrosis patients. The new fo...to be delivered directly to the site of,infection....ts of two,different doses of the new drug. Initial...
(Date:9/3/2008)...a, Sept. 4 /Xinhua--,Pharma...) today announced,that it has enrolled the first s...ial evaluating Bronchitol in cystic fibrosis suffe... hospitals across North,America, Argentina and Ger...xis seeks approval to market Bronchitol for cystic...
Breaking Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Body Image is a Concern for Students of All Ages 23875 1Body Image is a Concern for Students of All Ages 23875 2Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 1Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 2Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 1Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 2Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 1Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 2
... II GBM study presented at ASCO with cediranib - a... quarter of patients alive,and progression- free a...e/ -- Data for the,investigational agent cediranib...ing of the American Society of Clinical Oncology,(...blastoma (GBM),an invasive form of brain tumor wi...
...itive data on subcutaneous administration show pot...atients -, CHICAGO, June 04, 2007 /PRNewswire-Firs...nnounced the presentation of positive,data for VEL...,multiple myeloma (MM) who have received at least ... a Phase II trial for subcutaneous,(SC) administra...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...responsible for checking the profits and safety of... to the NHS. They have to monitor that only brande...ould be reasonable. The Pharmaceutical Price Regu...nization which monitors and legislates the agreeme...
...ve come up with a disaster-planning guide to help ...nted by tropical storms, hurricanes, tidal waves a...world, people are vulnerable to some sort of natur...ke, flood, hurricane, or tornado. In addition, ter...
...ed over the increasing malfunction of heart device... deaths between 1990 and 2002. The Food and Drug A...ng with physicians and heart-device manufacturers ...llators had failed between 2000 and 2003. Same num...
...he damages in the heart from the use of stem cells...s from mice to repair heart damage in sheep, repor...sue of The Lancet. Heart failure is a major cause ...es, occurring when cells within the heart are dama...
Other Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device.
Clinicians are demanding smaller, higher performing systems specifically designed to meet their clinical and operational challenges. The new Philips HD11 XE system provides a powerful architecture fo
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea
InfinixTM CF-i/SP brings revolutionary flexibility to floor-mounted X-ray systems. The unique design enables operators to move the C-arm around the exam table as needed to obtain the optimal angle fo
Medicine Products: